MedTrace Logo

PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer

NCT04404361 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2024-06-05

Study results available
· View outcomes & findings →

Summary

This is a Phase 2 randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of pacritinib in hospitalized patients with severe COVID-19 with or without cancer.

Conditions

Interventions

DRUG

Pacritinib

100 mg capsules

DRUG

Placebo

Placebo capsules matching pacritinib 100 mg capsules

Sponsors & Collaborators

  • CTI BioPharma

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-22
Primary Completion
2021-09-21
Completion
2021-09-21
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04404361 on ClinicalTrials.gov